Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
Список исп. литературыСкрыть список 1. McIntyre RS. Pharmacology and efficacy of asenapine for manic and mixed states in adults with bipolar disorder. Expert Rev Neurother 2010; 10 (5): 645–9. 2. McIntyre RS, Cohen M, Zhao J et al. A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disord 2009; 11 (7): 673–86. 3. McIntyre RS, Cohen M, Zhao J et al. Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Affect Disord 2010; 122 (l–2): 27–38. 4. McIntyre RS, Cohen M, Zhao J et al. Asenapine in the treatment of acute mania in bipolar I disorder: a double-blind 40-week extension study. J Affect Disord 2010; 126 (3): 358–65. 5. Szegedi A, Zhao J, van Willigenburg A et al. Effects of asenapine on depressive symptoms in patients with bipolar I disorder experiencing acute manic or mixed episodes: a post hoc analysis of two 3-week clinical trials. BMC Psychiat 2011; 11: 101. 6. Kane JM, Cohen M, Zhao J et al. Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. J Clin Psychopharmacol 2010; 30 (2): 106–15. 7. Kane JM, Mackle M, Snow-Adami L et al. A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment. J Clin Psychiat 2011; 72 (3): 349–55. 8. Tarazi FI, Moran-Gates T, Wong EH et al. Differential regional and dose-related effects of asenapine on dopamine receptor subtypes. Psycho-pharmacology (Berl) 2008; 198 (1): 103–11. 9. Tarazi FI, Choi YK, Gardner M et al. Asenapine exerts distinctive regional effects on ionotropic glutamate receptor subtypes in rat brain. Synapse 2009; 63 (5): 413–20. 10. Choi YK, Wong EH, Henry B et al. Repeated effects of asenapine on adrenergic and cholinergic muscarinic receptors. Int J Neuropsy Pharmacol 2010; 13 (3): 405–10. 11. Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5HT2- and D2-receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. J Clin Psychiat 1999; 156 (2): 286–93. 12. Seeman P. Targeting the dopamine D2-receptor in schizophrenia. Expert Opin Ther Targets 2006; 10 (4): 515–31. 13. Ghanbari R, Mansari M, Shahid M, Blier P. Electrophysiological characterization of the effects of asenapine at 5HTlA-, 5HT2A-, a2-adrenergic and D2-receptors in the rat brain. Eur Neuropsychopharmacol 2009; 19 (3): 177–87. 14. Franberg O, Marcus MM, Ivanov V et al. Asenapine elevates cortical dopamine, noradrenaline and serotonin release. Evidence for activation of cortical and subcortical dopamine systems by different mechanisms. Psychopharmacol (Berl) 2009; 204 (2): 251–64. 15. Marston HM, Martin FD, Papp M et al. Attenuation of chronic mild stress-induced «anhedonia» by asenapine is not associated with a «hedonic» profile in intracranial self-stimulation. J Psychopharmacol 2010.